RxDoctor Payments Data

Ashlie Glasgow, PA

Medical · Fort Washington, PANPI 1770062358

Payments from drug & device makers

$2,997in general payments, 2019–2025

Across 113 payments — averaging $26.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Astellas Pharma US Inc$397
  • Sumitomo Pharma America, Inc.$356
  • AstraZeneca$209
  • Convatec Inc.$124
  • Blue Earth Diagnostics$119
  • plus $667 from 15 others

What the payments were for

  • Travel & lodging$2187%
  • Food & beverage$2,52984%
  • Education$2508%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,997 in reported general payments places this provider in the 80th percentile of 2,594 medical providers in Pennsylvania.

See all medical providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$60,936
Medicare patients
205
Services billed
642

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron212$162,735
MyrbetriqMirabegron228$159,776
Methenamine Hippurate57$5,126
Estradiol63$4,622
Tolterodine Tartrate ErTolterodine Tartrate27$2,706
Tamsulosin Hcl77$1,303
Oxybutynin Chloride ErOxybutynin Chloride38$834
Alfuzosin Hcl ErAlfuzosin Hcl14$521
Solifenacin Succinate15$399
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst29$359
Trospium Chloride13$302
NitrofurantoinNitrofurantoin Macrocrystal11$250
Finasteride18$205
Cephalexin34$195
Ciprofloxacin Hcl19$130

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$356$162,735212 claims
Astellas Pharma US IncMyrbetriq$397$159,776228 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,594 medical providers in Pennsylvania.

Other medical in Fort Washington

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →